<DOC>
	<DOCNO>NCT01082926</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , cellular adoptive immunotherapy , may stimulate immune system different way stop tumor cell grow . Donor T cell treat laboratory may effective treatment malignant glioma . Aldesleukin may stimulate white blood cell kill tumor cell . Combining different type biological therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best way give therapeutic donor lymphocytes together aldesleukin treat patient stage III stage IV malignant glioma .</brief_summary>
	<brief_title>Phase I Study Cellular Immunotherapy Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions GRm13Z40-2 , An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified Express IL 13-Zetakine HyTK Resistant Glucocorticoids , Combination With Interleukin-2</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy research participant recurrent refractory/ progressive malignant glioma ( WHO Grades 3 4 ) . II . To assess safety convection enhance delivery ( CED ) recombinant human Interleukin-2 ( rhuIL-2 ) use conjunction GRm13Z40-2 CTL adoptive transfer . SECONDARY OBJECTIVES : I . To investigate ability 9- ( 4-fluoro-3-hydroxy-methyl-butyl ) guanine ( 18FHBG ) positron emission tomography PET image GRm13Z40-2 CTL 's research participant . II . To study impact concurrent dexamethasone administration tempo magnitude T cell allograft rejection response treat research participant track frequency anti-GRm13Z40-2 immune response serially acquire peripheral blood sample . III . To evaluate ganciclovir administration ablate transfer GRm13Z40-2 vivo significant graft-mediated toxicity encounter . OUTLINE : Patients receive GRm13Z40-2 therapeutic allogeneic lymphocytes intratumorally ( IT ) 10 minute day 1 3 aldesleukin IT 3 hour day 2-5 ( day 1-5 week 2 ) . Treatment repeat every week 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow annually least 15 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histological verification grade III IV MG original diagnosis Radiographic evidence progression/recurrence measurable disease 12 week end radiation therapy Expression IL13Ralpha2 immunohistochemistry Karnofsky performance status ( KPS ) &gt; = 60 Disease recurrence/progression cerebral hemisphere , least one area enhancement amenable biopsy protocol enrollment follow location : Adjacent near previous resection cavity Distant primary location ; include tumor spread contralateral hemisphere , corpus callosum , thalamus , basal ganglion , subependymal location Research participant recover toxicity prior therapy ; interval least 12 week must elapse since completion radiation therapy ; least 6 week since completion nitrosoureacontaining chemotherapy regimen ; least 4 week since completion nonnitrosoureacontaining cytotoxic chemotherapy regimen ; patient 's recent treatment target agent , s/he recover toxicity target agent , wait period 2 week need last dose start study treatment , exception bevacizumab wash period least 4 week require start study treatment History prior treatment Temodar evidence intolerance ; documentation intolerance Temodar require Creatinine &lt; 1.6 White blood cell ( WBC ) &gt; = 2,000/dl ( absolute neutrophil count [ ANC ] &gt; 1,000 ) Platelets &gt; = 100,000/dl unsupported transfusion growth factor , international normalize ratio ( INR ) &lt; 1.3 Bilirubin &lt; 1.5 Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) &lt; 2 X upper limit normal Female research participant childbearing potential must pregnant evidenced serum betaHCG pregnancy test obtain within 7 day enrollment Research participant reproductive potential must agree use effective contraception participation protocol In opinion neurosurgeon , research participant require ongoing dexamethasone therapy Survival expectation less 4 week Pulmonary Requirement supplemental oxygen use expect resolve within 2 week , Cardiac Uncontrolled cardiac arrhythmia , hypotension require pressor support , Renal Dialysis dependent , Neurologic refractory seizure disorder , clinically evident progressive encephalopathy Tumors follow characteristic : Large tumor recurrence cause significant symptom brain shift mass effect , thus require `` decompressive '' craniotomy Tumors locate primarily basal ganglion thalamus Tumors significant involvement midbrain , cerebellum , pons medulla exclude due neurological risk associate edema exacerbation therapy Research participant nonmalignant intercurrent illness either poorly control currently available treatment , severity investigator deem unwise enter research participant protocol shall ineligible Positive human immunodeficiency virus ( HIV ) serology base test within 4 week enrollment Research participant treat severe infection recover major surgery ineligible recovery deem complete investigator Failure understand basic element protocol and/or risks/benefits participate pilot study History ganciclovir and/or magnetic resonance imaging ( MRI ) contrast allergy intolerance History intolerance IL2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>Los Angeles</keyword>
</DOC>